Stocks Screener

Search any stock or ticker

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

How This Company Makes Money

Dividend Analysis AUROPHARMA

Max Ratio

0.20

Dividend Yield

0.33 %

5Y Dividend Growth

-40.00 %

Consecutive Years

5Y Average Payout Ratio

9.60 %

Dividend History AUROPHARMA

1 year
3 years
5 years
10 years
15 years
11/21/2021 - 11/28/2021
Forward Annual Dividend Yield 0.33 %
Consecutive Years 0
Forward Annual Dividend 4.00 INR
Consistent Years 0
Dividend CAGR 3Y -30.66 %
Continuous Dividends
Dividend CAGR 5Y -9.71 %
Payout Ratio TTM 6.79 %
Dividend CAGR 10Y -0.80 %
Ex Dividend Date 08/08/2025

The 5 Pillars Formula Checklist

The Five-Pillar Secret Formula Checklist is our simple, proven way to separate strong, lasting businesses from the rest. We look at five key pillars—sales growth, profit growth, Net Income, dividend safety, and debt levels. Together with Financial Score, they tell us if a company can keep growing, stay financially solid, and reliably pay dividends for decades.

Sales Growth AUROPHARMA

Sales Growth – The Foundation of a Strong Business. Consistent revenue growth over the past 10-15 years is a key sign of a thriving company. It shows that demand for its products and services is increasing, allowing it to expand operations, gain market share, and invest in future growth.
1 year
3 years
5 years
10 years

Profit Growth / Profit Margin AUROPHARMA

The Fuel for Company Growth. Revenue alone isn’t enough—what truly matters is how efficiently a company turns that revenue into consistent, growing profits. Profitability is the foundation of sustainable growth and long-term financial strength.
1 year
3 years
5 years
10 years

Net Income AUROPHARMA

The True Measure of Financial Strength. Net income is what remains after all expenses, taxes, and costs. This is the company’s real earning power.
1 year
3 years
5 years
10 years

Payout Ratio TTM AUROPHARMA

Dividend Payout Safety – Protecting Your Passive Income. A high dividend yield is meaningless if the company can’t afford to sustain it. We evaluate payout ratios to ensure the company is not overextending itself. The best companies have a balanced approach—paying generous dividends while still reinvesting in future growth. Dividend safety is crucial for long-term income stability.
1 year
3 years
5 years
10 years
15 years
11/21/2021 - 11/28/2021

Debt Ratio AUROPHARMA

Debt Burden – Avoiding Financial Traps. Too much debt can cripple a company, even if its revenues and profits look great. We analyze how well a company manages its liabilities, ensuring that debt levels are under control.
1 year
3 years
5 years
10 years
11/21/2021 - 11/28/2021

Full Financial Performance

See how the company makes money over time—revenue, profits, dividends, and more. The charts on the right give you a quick view of growth trends so you can instantly spot consistency or red flags.

Aurobindo Pharma Limited AUROPHARMA

1 year
3 years
5 years
10 years
Results 2019 Dynamics
* The data for this period has not yet been published

Bottom Line

Valuation Check

Shows if a stock is priced fairly by looking at peers and the company’s own history — a quick way to see if it’s a bargain or overpriced.

Value vs Peers

The company is measured against at least 10 rivals in the same sector. If it earns 25% more profit per share than the average, it’s Undervalued. If it earns 25% less, it’s Overvalued. In short: stronger earnings per share mean you’re getting a bargain, weaker ones mean you’re overpaying.

Value vs Itself AUROPHARMA

P/E shows how many dollars investors pay in the stock price for each $1 of profit the company earns per share. Today’s P/E is compared with the company’s 10-year average. If the ratio is above that norm, you’re paying up for each dollar of profit. If it’s below, you’re getting more earnings for less.
1 year
3 years
5 years
10 years
11/21/2021 - 11/28/2021
Trailing PE 20.78
Forward PE 8.36
Enterprise Value Revenue 2.13
Price Sales TTM 2.18
Enterprise Value EBITDA 9.75
Price Book MRQ 2.00

Aurobindo Pharma Limited Dividends: 0.33 % Yield, History, Payment Schedule

AUROPHARMA
Current price
1 223.10 INR +7.68 INR (+0.63%)
Last closed 1 208.90 INR
ISIN INE406A01037
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange National Stock Exchange of India
Capitalization 711 571 237 695 INR
Yield for 12 month -1.65 %
1Y
3Y
5Y
10Y
15Y
AUROPHARMA
11/21/2021 - 11/28/2021

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Advanced Highlights

Current Year

+317 769 966 976 INR

Last Year

+290 505 664 807 INR

Current Quarter

+82 996 123 585 INR

Last Quarter

+78 813 512 401 INR

Current Year

+182 704 962 127 INR

Last Year

+160 430 724 541 INR

Current Quarter

+32 457 607 623 INR

Last Quarter

+46 366 923 255 INR
EBITDA 65 431 279 231 INR
Operating Margin TTM 15.07 %
Price to Earnings 20.78
Return On Assets TTM 6.25 %
PEG Ratio
Return On Equity TTM 10.38 %
Wall Street Target Price 116 564.92 INR
Revenue TTM 325 690 749 714 INR
Book Value 604.41 INR
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 6.30 %
Dividend Yield 0.33 %
Gross Profit TTM 187 669 490 615 INR
Earnings per share 58.97 INR
Diluted Eps TTM 58.97 INR
Most Recent Quarter III 2025
Quarterly Earnings Growth YOY 4.40 %
Profit Margin 10.53 %

Technical Indicators AUROPHARMA

For 52 Weeks

1 007.91 INR 1 353.40 INR
50 Day MA 1 149.60 INR
Shares Short Prior Month
200 Day MA 1 135.09 INR
Short Ratio
Shares Short
Short Percent